FDA Inspection 1247313 — Carter BloodCare

Carter BloodCare — FEI 3012540622

The FDA completed an inspection of Carter BloodCare on Jun 27, 2024 in Frisco, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.

Inspection Details

Classification
No Action Indicated (NAI)
End Date
Jun 27, 2024
Fiscal Year
2024
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Frisco, TX (United States)